Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Aug 9;23(1):202.
doi: 10.1186/s12931-022-02126-2.

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

Elisabeth De Leeuw #  1   2   3 , Karel F A Van Damme #  1   2   3 , Jozefien Declercq #  1   2   3 , Cedric Bosteels #  1   2   3 , Bastiaan Maes  1   2   3 , Simon J Tavernier  1   2   4 , Laurent Detalle  5 , Trevor Smart  6 , Sophie Glatt  6 , Nincy Debeuf  1   2 , Julie Deckers  1   2 , Sahine Lameire  1   2 , Stefaan J Vandecasteele  7 , Nikolaas De Neve  8 , Ingel K Demedts  9 , Elke Govaerts  10 , Christiane Knoop  11 , Karolien Vanhove  12 , Michel Moutschen  13 , Wim Terryn  14 , Pieter Depuydt  2   15 , Eva Van Braeckel  2   3 , Filomeen Haerynck  2   4 , Tine C J Hendrickx  16 , Vanessa Parrein  17 , Marianna Lalla  6 , Claire Brittain  6 , Bart N Lambrecht  18   19   20
Affiliations
Randomized Controlled Trial

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

Elisabeth De Leeuw et al. Respir Res. .

Abstract

Background: The efficacy and safety of complement inhibition in COVID-19 patients is unclear.

Methods: A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO2/FiO2 below 350 mmHg) were randomized (2:1 ratio) to receive standard of care with or without the C5 inhibitor zilucoplan daily for 14 days, under antibiotic prophylaxis. The primary outcome was improvement in oxygenation at day 6 and 15.

Results: 81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 years. The mean improvement in PaO2/FiO2 from baseline to day 6 was 56.4 mmHg in the zilucoplan group and 20.6 mmHg in the control group (mean difference + 35.8; 95% confidence interval (CI) - 9.4 to 80.9; p = 0.12), an effect also observed at day 15. Day 28 mortality was 9% in the zilucoplan and 21% in the control group (odds ratio 0.4; 95% CI 0.1 to 1.5). At long-term follow up, the distance walked in a 6-min test was 539.7 m in zilucoplan and 490.6 m in the control group (p = 0.18). Zilucoplan lowered serum C5b-9 (p < 0.001) and interleukin-8 (p = 0.03) concentration compared with control. No relevant safety differences between the zilucoplan and control group were identified.

Conclusion: Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of respiratory function (PaO2/FiO2) and clinical outcome (mortality and 6-min walk test) suggest that C5 inhibition might be beneficial, although this requires further research in larger randomized studies.

Trial registration: ClinicalTrials.gov NCT04382755.

Keywords: COVID-19; Complement 5; Complement system; Systemic inflammation.

PubMed Disclaimer

Conflict of interest statement

CeB, EDL, JoD, BM, KVD have received an FWO PhD Fellowship. ND, JuD, SJT have received an FWO Postdoctoral Grant. ClB, LD, SG, ML, TS are employed by UCB. VP is employed by Sillar Clinical N.V. ClB, LD, ML, TS hold stock or stock options from UCB. LD holds stock or stock options from Sanofi. TS holds stock or stock options from Pfizer and Lilly. ClB, BNL, EVB have contributed or participated on a DSMB or Advisory Board. BNL has received a grant from Partner Therapeutics, Inc., has received consulting fees and payments from Sanofi and GSK and holds stock options from Argenx. EVB has received a grant from Ghent University, is principal investigator in a trial sponsored by Exevir Bio and has received consulting fees or payments from GSK, MDS and Gilead. ID, NDN, PD, EG, FH, TH, CK, SL, MM, WT, SV report no competing interests.

Figures

Fig. 1
Fig. 1
Enrollment and randomization
Fig. 2
Fig. 2
Primary outcome and secondary clinical outcome. ECMO extracorporeal membrane oxygenation, FiO2 fraction of inspired oxygen, LSMean Least Square Means, PaO2 partial pressure of arterial oxygen
Fig. 3
Fig. 3
Cytokines and chemokines. GeoMean geometric mean. No adjustments for multiplicity were made
See this image and copyright information in PMC

References

    1. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383:120–128. doi: 10.1056/NEJMoa2015432. - DOI - PMC - PubMed
    1. Carvelli J, Demaria O, Vely F, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature. 2020;588:146–150. doi: 10.1038/s41586-020-2600-6. - DOI - PMC - PubMed
    1. Ma L, Sahu SK, Cano M, et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci Immunol. 2021 doi: 10.1126/sciimmunol.abh2259. - DOI - PMC - PubMed
    1. Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. doi: 10.1016/j.trsl.2020.04.007. - DOI - PMC - PubMed
    1. Satyam A, Tsokos MG, Brook OR, Hecht JL, Moulton VR, Tsokos GC. Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. Clin Immunol. 2021;226:108716. doi: 10.1016/j.clim.2021.108716. - DOI - PMC - PubMed

Publication types

Associated data